<DOC>
	<DOCNO>NCT00787293</DOCNO>
	<brief_summary>Improvement heart failure moderate severe mitral regurgitation use percutaneously deliver implantable device .</brief_summary>
	<brief_title>Study Safety Efficacy Percutaneous Reduction Mitral Valve Regurgitation Heart Failure Patients</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Functional MR 2+ 4+ Symptomatic heart failure , NYHA Class II IV LVEF &gt; 25 % &lt; 50 % OR dilate mitral annulus &gt; 30mm MR organic origin Severe mitral leaflet tether History MI PCI within 60 day study procedure Inability walk minimum 100 meter 6 minute Significant leave main stenosis proximal circumflex stent Indication nonpatent CSO discontinuous CSGCVAIV Biventricular lead CS device impede device placement Severe aortic valvular disease Chronic corticosteroid use &lt; 20mg prednisone arthritis Significant comorbidities</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Mitral Regurgitation</keyword>
	<keyword>Percutaneous</keyword>
	<keyword>Coronary sinus</keyword>
</DOC>